Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Colorectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 26Breast Neoplasms 26Lung Neoplasms 24Colonic Neoplasms 18Head and Neck Neoplasms 16Rectal Neoplasms 14Prostatic Neoplasms 11Sarcoma 10Neoplasm Metastasis 9Pancreatic Neoplasms 8Neoplasms 7Mouth Neoplasms 7Melanoma 7Esophageal Neoplasms 7Adenomatous Polyposis Coli 7Ovarian Neoplasms 6Glioblastoma 6Precancerous Conditions 5Neuroblastoma 5Liver Neoplasms 5Central Nervous System Neoplasms 5Carcinoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Oropharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

pembrolizumab 161Carboplatin 145Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 38sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Celecoxib × Clear all
NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Université de Sherbrooke

Phase 2 Recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
5 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡